Novartis reports Phase lllb positive data of Cosentyx vs Stelara

17th January 2018 (Last Updated January 17th, 2018 00:00)

Novartis has reported positive results from a Phase lllb trial evaluating Cosentyx (secukinumab) in comparison with Stelara (ustekinumab) for the treatment of psoriasis.

Novartis has reported positive results from a Phase lllb trial evaluating Cosentyx (secukinumab) in comparison with Stelara (ustekinumab) for the treatment of psoriasis.

Findings of the CLARITY trial showed the superiority of Cosentyx (secukinumab) compared with Stelara (ustekinumab) in delivering clear and almost clear skin in adults with moderate-to-severe plaque psoriasis at 12 weeks.

Results also showed that Cosentyx was found to be more effective than Stelara in achieving sustained skin clearance (psoriasis area and severity index90) at week 52 of the trial.

In addition, Cosentyx demonstrated significantly improved results than Stelara in delivering clear and almost clear skin at 12 weeks and 16 weeks.

"Cosentyx demonstrated significantly improved results than Stelara in delivering clear and almost clear skin at 12 weeks and 16 weeks."

Novartis further noted that 66.5% and 72.3% of patients treated with Cosentyx achieved both co-primary endpoints PASI 90 and Investigator's Global Assessment (IGA) mod 2011 0/1 respectively. This compared to 47.9% and 55.4% patients respectively treated with Stelara.

The CLARITY trial is a 52-week, multicentre, randomised, double-blind study to demonstrate the effectiveness of Cosentyx (secukinumab) 300mg vs Stelara (ustekinumab) in moderate-to-severe plaque psoriasis patients.

Its co-primary endpoints were 90% or more improvement from Baseline PASI 90 and mod 2011 0/1 (clear or almost clear) response rates at week 12.

Key secondary endpoints included demonstrating the effectiveness of secukinumab vs ustekinumab with respect to PASI 75 at week four, PASI 75 and 100 at week 12; and PASI 75, 90, 100 and IGA mod 2011 0/1 at week 16.

The trial has met all these endpoints, noted Novartis.